{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:30:24Z","timestamp":1787574624741,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Consejo Nacional de Ciencia y Tecnolog\u00eda, Guatemala, Guatemala","award":["Findecyt\/Gestiona I+D 01-2024"],"award-info":[{"award-number":["Findecyt\/Gestiona I+D 01-2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01157-5","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T15:54:21Z","timestamp":1781366061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1481-8116","authenticated-orcid":false,"given":"Lesly Yanira","family":"Xajil-Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5927-4992","authenticated-orcid":false,"given":"Jes\u00fas Alonso","family":"G\u00e1ndara-Mireles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3789-6189","authenticated-orcid":false,"given":"Mariela","family":"Guerra-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9042-0839","authenticated-orcid":false,"given":"Rodrigo Jos\u00e9 Vargas","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2004-3131","authenticated-orcid":false,"given":"Andrea Mariela Ruano","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2817-8081","authenticated-orcid":false,"given":"Dulce Sofia","family":"Oca\u00f1a-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-4556","authenticated-orcid":false,"given":"Ismael","family":"Lares-Asseff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-6852","authenticated-orcid":false,"given":"Oscar","family":"C\u00f3bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-0209","authenticated-orcid":false,"given":"Sindy M\u00e9ndez","family":"Soveranis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-055X","authenticated-orcid":false,"given":"Leslie","family":"Patr\u00f3n-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1874-3975","authenticated-orcid":false,"given":"Horacio","family":"Almanza-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1520-8715","authenticated-orcid":false,"given":"Randall","family":"Lou-Meda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"1157_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/phar.2480","volume":"41","author":"L Schumacher","year":"2021","unstructured":"Schumacher L, Leino AD, Park JM. Tacrolimus Intrapatient Variability in Solid Organ Transplantation: A Multiorgan Perspective. Pharmacotherapy. 2021;41:103\u201318. https:\/\/doi.org\/10.1002\/phar.2480.","journal-title":"Pharmacotherapy"},{"key":"1157_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/17425255.2023.2250251","volume":"19","author":"MR Schagen","year":"2023","unstructured":"Schagen MR, Volarevic H, Francke MI, Sassen SDT, Reinders MEJ, Hesselink DA, De Winter BCM. Individualized Dosing Algorithms for Tacrolimus in Kidney Transplant Recipients: Current Status and Unmet Needs. Expert Opin Drug Metab Toxicol. 2023;19:429\u201345. https:\/\/doi.org\/10.1080\/17425255.2023.2250251.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1157_CR3","doi-asserted-by":"publisher","unstructured":"Yu M, Liu M, Zhang W, Ming Y, Pharmacokinetics. pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. CDM 2018;19:513\u2013522. https:\/\/doi.org\/10.2174\/1389200219666180129151948.","DOI":"10.2174\/1389200219666180129151948"},{"key":"1157_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"K Birdwell","year":"2015","unstructured":"Birdwell K, Decker B, Barbarino J, Peterson J, Stein C, Sadee W, Wang D, Vinks A, He Y, Swen J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharma Ther. 2015;98:19\u201324. https:\/\/doi.org\/10.1002\/cpt.113.","journal-title":"Clin Pharma Ther"},{"key":"1157_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/PGPM.S107710","volume":"11","author":"L Chen","year":"2018","unstructured":"Chen L, Prasad GVR. CYP3A5 Polymorphisms in Renal Transplant Recipients: Influence on Tacrolimus Treatment. PGPM. 2018;11:23\u201333. https:\/\/doi.org\/10.2147\/PGPM.S107710.","journal-title":"PGPM"},{"key":"1157_CR6","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1111\/bcp.14110","volume":"85","author":"TM Nanga","year":"2019","unstructured":"Nanga TM, Doan TTP, Marquet P, Musuamba FT. Toward a Robust Tool for Pharmacokinetic-based Personalization of Treatment with Tacrolimus in Solid Organ Transplantation: A Model\u2010based Meta\u2010analysis Approach. Brit J Clin Pharma. 2019;85:2793\u2013823. https:\/\/doi.org\/10.1111\/bcp.14110.","journal-title":"Brit J Clin Pharma"},{"key":"1157_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/jcpt.12523","volume":"42","author":"HJ Zhang","year":"2017","unstructured":"Zhang HJ, Li DY, Zhu HJ, Fang Y, Liu TS. Tacrolimus Population Pharmacokinetics According to CYP3A5 Genotype and Clinical Factors in Chinese Adult Kidney Transplant Recipients. J Clin Pharm Ther. 2017;42:425\u201332. https:\/\/doi.org\/10.1111\/jcpt.12523.","journal-title":"J Clin Pharm Ther"},{"key":"1157_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/bcp.12649","volume":"80","author":"CO Jacobo-Cabral","year":"2015","unstructured":"Jacobo-Cabral CO, Garc\u00eda\u2010Roca P, Romero\u2010Tejeda EM, Reyes H, Medeiros M, Casta\u00f1eda\u2010Hern\u00e1ndez G, Troc\u00f3niz IF. Population Pharmacokinetic Analysis of Tacrolimus in Mexican Paediatric Renal Transplant Patients: Role of CYP3A5 Genotype and Formulation. Brit J Clin Pharma. 2015;80:630\u201341. https:\/\/doi.org\/10.1111\/bcp.12649.","journal-title":"Brit J Clin Pharma"},{"key":"1157_CR9","doi-asserted-by":"publisher","first-page":"e13391","DOI":"10.1111\/petr.13391","volume":"23","author":"J Rubik","year":"2019","unstructured":"Rubik J, Debray D, Iserin F, Vondrak K, Sellier-Leclerc A, Kelly D, Czubkowski P, Webb NJA, Riva S, D\u2019Antiga L, et al. Comparative Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate\u2010release Tacrolimus to Prolonged\u2010release Tacrolimus Formulation. Pediatr Transplant. 2019;23:e13391. https:\/\/doi.org\/10.1111\/petr.13391.","journal-title":"Pediatr Transplant"},{"key":"1157_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.7196\/SAMJ.2020.v110i2.13969","volume":"110","author":"WK Muller","year":"2020","unstructured":"Muller WK, Dandara C, Manning K, Mhandire D, Ensor J, Barday Z, Freercks R. CYP3A5 Polymorphisms and Their Effects on Tacrolimus Exposure in an Ethnically Diverse South African Renal Transplant Population. S Afr Med J. 2020;110:159. https:\/\/doi.org\/10.7196\/SAMJ.2020.v110i2.13969.","journal-title":"S Afr Med J"},{"key":"1157_CR11","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1128\/AAC.47.9.2888-2891.2003","volume":"47","author":"VH Tam","year":"2003","unstructured":"Tam VH, Preston SL, Drusano GL. Optimal Sampling Schedule Design for Populations of Patients. Antimicrob Agents Chemother. 2003;47:2888\u201391. https:\/\/doi.org\/10.1128\/AAC.47.9.2888-2891.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"1157_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00467-018-3892-8","volume":"34","author":"A Prytu\u0142a","year":"2019","unstructured":"Prytu\u0142a A, Van Gelder T. Clinical Aspects of Tacrolimus Use in Paediatric Renal Transplant Recipients. Pediatr Nephrol. 2019;34:31\u201343. https:\/\/doi.org\/10.1007\/s00467-018-3892-8.","journal-title":"Pediatr Nephrol"},{"key":"1157_CR13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0b013e31823415cc","volume":"33","author":"JE Wallin","year":"2011","unstructured":"Wallin JE, Bergstrand M, Wilczek HE, Nydert PS, Karlsson MO, Staatz CE. Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation Clearance. Ther Drug Monit. 2011;33:663\u201372. https:\/\/doi.org\/10.1097\/FTD.0b013e31823415cc.","journal-title":"Ther Drug Monit"},{"key":"1157_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/clpt.2009.210","volume":"86","author":"W Zhao","year":"2009","unstructured":"Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, Andr\u00e9 JL, et al. Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients. Clin Pharmacol Ther. 2009;86:609\u201318. https:\/\/doi.org\/10.1038\/clpt.2009.210.","journal-title":"Clin Pharmacol Ther"},{"key":"1157_CR15","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.8129","author":"D Wang","year":"2019","unstructured":"Wang D, Chen X, Xu H, Li Z. Population Pharmacokinetics of Tacrolimus in Pediatric Patients with Systemic\u2013onset Juvenile Idiopathic Arthritis: Initial Dosage Recommendations. Exp Ther Med. 2019. https:\/\/doi.org\/10.3892\/etm.2019.8129.","journal-title":"Exp Ther Med"},{"key":"1157_CR16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00228-024-03717-2","volume":"80","author":"S Yang","year":"2024","unstructured":"Yang S, Wei J, Pan X, Li Z, Zhang X, Li Z, Dong X, Hua Z, Li X. Development and Validation of Individualized Tacrolimus Dosing Software for Chinese Pediatric Liver Transplantation Patients: A Population Pharmacokinetic Approach. Eur J Clin Pharmacol. 2024;80:1409\u201320. https:\/\/doi.org\/10.1007\/s00228-024-03717-2.","journal-title":"Eur J Clin Pharmacol"},{"key":"1157_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jcph.2162","volume":"63","author":"M Zuo","year":"2023","unstructured":"Zuo M, Shang Y, Guo Y, Sun Y, Xu G, Chen J, Zhu L. Population Pharmacokinetics of Tacrolimus in Pediatric Patients With Umbilical Cord Blood Transplant. J Clin Pharma. 2023;63:298\u2013306. https:\/\/doi.org\/10.1002\/jcph.2162.","journal-title":"J Clin Pharma"},{"key":"1157_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40262-016-0390-7","volume":"55","author":"AA Prytu\u0142a","year":"2016","unstructured":"Prytu\u0142a AA, Cransberg K, Bouts AHM, Van Schaik RHN, De Jong H, De Wildt SN, Math\u00f4t RAA. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clin Pharmacokinet. 2016;55:1129\u201343. https:\/\/doi.org\/10.1007\/s40262-016-0390-7.","journal-title":"Clin Pharmacokinet"},{"key":"1157_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40262-017-0567-8","volume":"57","author":"LM Andrews","year":"2018","unstructured":"Andrews LM, Hesselink DA, Van Gelder T, Koch BCP, Cornelissen EAM, Br\u00fcggemann RJM, Van Schaik RHN, De Wildt SN, Cransberg K, De Winter BC. M. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. Clin Pharmacokinet. 2018;57:475\u201389. https:\/\/doi.org\/10.1007\/s40262-017-0567-8.","journal-title":"Clin Pharmacokinet"},{"key":"1157_CR20","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/jcm9072193","volume":"9","author":"C Thongprayoon","year":"2020","unstructured":"Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Bathini T, Pivovarova A, Smith JR, Cheungpasitporn W. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. JCM. 2020;9:2193. https:\/\/doi.org\/10.3390\/jcm9072193.","journal-title":"JCM"},{"key":"1157_CR21","doi-asserted-by":"publisher","first-page":"674117","DOI":"10.3389\/fphar.2021.674117","volume":"12","author":"S Contreras-Castillo","year":"2021","unstructured":"Contreras-Castillo S, Plaza A, Stojanova J, Navarro G, Carmona R, Corval\u00e1n F, Cerpa L, Sandoval C, Mu\u00f1oz D, Leiva M, et al. Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients. Front Pharmacol. 2021;12:674117. https:\/\/doi.org\/10.3389\/fphar.2021.674117.","journal-title":"Front Pharmacol"},{"key":"1157_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13737-016-0031-6","volume":"5","author":"ASR Zaltzman","year":"2016","unstructured":"Zaltzman ASR, Glick LA, Zaltzman JS, Nash M, Huang M, Prasad GVR. The Role of CYP3A5 Polymorphism and Dose Adjustments Following Conversion of Twice-Daily to Once-Daily Tacrolimus in Renal Transplant Recipients. Transpl Res. 2016;5:2. https:\/\/doi.org\/10.1186\/s13737-016-0031-6.","journal-title":"Transpl Res"},{"key":"1157_CR23","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/lt.25495","volume":"25","author":"N Riva","year":"2019","unstructured":"Riva N, Woillard J, Distefano M, Moragas M, Dip M, Halac E, C\u00e1ceres Guido P, Licciardone N, Mangano A, Bosaleh A, et al. Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients. Liver Transpl. 2019;25:1397\u2013407. https:\/\/doi.org\/10.1002\/lt.25495.","journal-title":"Liver Transpl"},{"key":"1157_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jcph.1325","volume":"59","author":"O Campagne","year":"2019","unstructured":"Campagne O, Mager DE, Tornatore KM. Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? J Clin Pharma. 2019;59:309\u201325. https:\/\/doi.org\/10.1002\/jcph.1325.","journal-title":"J Clin Pharma"},{"key":"1157_CR25","doi-asserted-by":"publisher","first-page":"726784","DOI":"10.3389\/fphar.2021.726784","volume":"12","author":"L Srinivas","year":"2021","unstructured":"Srinivas L, Gracious N, Nair RR. Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients. Front Pharmacol. 2021;12:726784. https:\/\/doi.org\/10.3389\/fphar.2021.726784.","journal-title":"Front Pharmacol"},{"key":"1157_CR26","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1097\/TP.0000000000003660","volume":"105","author":"JG Yoon","year":"2021","unstructured":"Yoon JG, Song SH, Choi S, Oh J, Jang I-J, Kim YJ, Moon S, Kim B-J, Cho Y, Kim HK, et al. Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing. Transplantation. 2021;105:2213\u201325. https:\/\/doi.org\/10.1097\/TP.0000000000003660.","journal-title":"Transplantation"},{"key":"1157_CR27","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/jcph.1118","volume":"58","author":"O Campagne","year":"2018","unstructured":"Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM. Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients. J Clin Pharma. 2018;58:1184\u201395. https:\/\/doi.org\/10.1002\/jcph.1118.","journal-title":"J Clin Pharma"},{"key":"1157_CR28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/bcp.12276","volume":"77","author":"N Kassir","year":"2014","unstructured":"Kassir N, Labb\u00e9 L, Delaloye J-R, Mouksassi M-S, Lapeyraque A-L, Alvarez F, Lallier M, Beaunoyer M, Th\u00e9or\u00eat Y, Litalien C. Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Paediatric Liver Transplant Recipients: Tacrolimus in Paediatric Liver Transplant Recipients. Br J Clin Pharmacol. 2014;77:1051\u201363. https:\/\/doi.org\/10.1111\/bcp.12276.","journal-title":"Br J Clin Pharmacol"},{"key":"1157_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","volume":"61","author":"AS Darwich","year":"2021","unstructured":"Darwich AS, Polasek TM, Aronson JK, Ogungbenro K, Wright DFB, Achour B, Reny J-L, Daali Y, Eiermann B, Cook J, et al. Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. Annu Rev Pharmacol Toxicol. 2021;61:225\u201345. https:\/\/doi.org\/10.1146\/annurev-pharmtox-033020-113257.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1157_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG. Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1157_CR31","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1111\/bcp.16172","volume":"90","author":"A Saqr","year":"2024","unstructured":"Saqr A, Al-Kofahi M, Mohamed M, Dorr C, Remmel RP, Onyeaghala G, Oetting WS, Guan W, Mannon RB, Matas AJ, et al. Steroid\u2013Tacrolimus Drug\u2013Drug Interaction and the Effect of CYP3A Genotypes. Brit J Clin Pharma. 2024;90:2837\u201348. https:\/\/doi.org\/10.1111\/bcp.16172.","journal-title":"Brit J Clin Pharma"},{"key":"1157_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/00498254.2019.1601791","volume":"50","author":"D Wang","year":"2020","unstructured":"Wang D, Chen X, Xu H, Li Z. Population Pharmacokinetics and Dosing Regimen Optimization of Tacrolimus in Chinese Pediatric Hematopoietic Stem Cell Transplantation Patients. Xenobiotica. 2020;50:188\u201395. https:\/\/doi.org\/10.1080\/00498254.2019.1601791.","journal-title":"Xenobiotica"},{"key":"1157_CR33","doi-asserted-by":"publisher","unstructured":"Rower JE, Stockmann C, Linakis MW, Kumar SS, Liu X, Korgenski EK, Sherwin CMT, Molina KM. Predicting Tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model. bmjpo. 2017;1(e000147). https:\/\/doi.org\/10.1136\/bmjpo-2017-000147.","DOI":"10.1136\/bmjpo-2017-000147"},{"key":"1157_CR34","doi-asserted-by":"publisher","first-page":"1160752","DOI":"10.3389\/frtra.2023.1160752","volume":"2","author":"L Henkel","year":"2023","unstructured":"Henkel L, Jehn U, Th\u00f6lking G, Reuter S. Tacrolimus\u2014Why Pharmacokinetics Matter in the Clinic. Front Transpl. 2023;2:1160752. https:\/\/doi.org\/10.3389\/frtra.2023.1160752.","journal-title":"Front Transpl"},{"key":"1157_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/FTD.0000000000000955","volume":"44","author":"A Mendoza Rojas","year":"2022","unstructured":"Mendoza Rojas A, Hesselink DA, Van Besouw NM, Dieterich M, De Kuiper R, Baan CC, Van Gelder T. High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression Are Associated With Adverse Kidney Transplant Outcomes. Ther Drug Monit. 2022;44:369\u201376. https:\/\/doi.org\/10.1097\/FTD.0000000000000955.","journal-title":"Ther Drug Monit"},{"key":"1157_CR36","doi-asserted-by":"publisher","first-page":"e1439","DOI":"10.1097\/TXD.0000000000001439","volume":"9","author":"L Haverals","year":"2023","unstructured":"Haverals L, Roosens L, Wouters K, Marquet P, Monchaud C, Massart A, Abramowicz D, Hellemans R. Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose? Transplantation Direct. 2023;9:e1439. https:\/\/doi.org\/10.1097\/TXD.0000000000001439.","journal-title":"Transplantation Direct"},{"key":"1157_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41397-019-0144-7","volume":"20","author":"AR Khan","year":"2020","unstructured":"Khan AR, Raza A, Firasat S, Abid A. CYP3A5 Gene Polymorphisms and Their Impact on Dosage and Trough Concentration of Tacrolimus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis. Pharmacogenomics J. 2020;20:553\u201362. https:\/\/doi.org\/10.1038\/s41397-019-0144-7.","journal-title":"Pharmacogenomics J"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01157-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01157-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01157-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:09:22Z","timestamp":1787573362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01157-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01157-5","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"112"}}